Ocugen licenses OCU400 to Celairis for Australia, New Zealand and ASEAN markets

By Public Technologies
  • Ocugen granted Celairis exclusive commercialization rights to investigational retinitis pigmentosa gene therapy OCU400 in Australia, New Zealand and ASEAN markets.
  • License fees and potential milestones total up to $7.1 million, including $6.1 million tied to upfront payment and top-line results.
  • The deal also provides a high single-digit royalty on net sales and 50% of regional gross profits from OCU400 net sales.
  • Celairis will handle regional regulatory submissions, market access and commercialization; a planned supply agreement would cover manufacturing by the developer.
  • Phase 3 top-line results are expected in the first quarter of 2027, with regional regulatory submissions expected following planned global filings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100700PRIMZONEFULLFEED9874088) on November 10, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk